CPR Therapeutics
CPR Therapeutics Inc. is a Vermont-based medical device startup dedicated to developing advanced, multimodal, automated cardiopulmonary resuscitation (CPR) systems. Funded by NIH and NSF, the company aims to significantly improve survival rates from sudden cardiac arrest by creating innovative, non-invasive CPR devices that enhance blood flow and electrical counter-shock efficacy. Their technology is designed to be more effective and safer than current manual and automated CPR methods, with a focus on clinical impact and addressing a major unmet medical need.
Industries
Nr. of Employees
small (1-50)
Patents
Methods and devices to improve the efficacy of mechanical cardiopulmonary resuscitation by changing the position of chest compression
US-11679059-B2
View Details
Methods and devices to improve the efficacy of mechanical cardiopulmonary resuscitation by changing the position of chest compression
US-11679059-B2
View DetailsProducts
Multimodal automated cardiopulmonary resuscitation system
An integrated automated CPR system that synchronizes multiple mechanical pump modalities (circumferential thoracic and abdominal actuation) with electrical countershock to increase blood flow during cardiac arrest.
Cath lab–optimized circumferential constriction system (radiolucent variant)
Device variant and materials/design optimized for use inside catheterization/cath lab environments with radiolucent components to minimize imaging interference during interventional procedures.
Multimodal automated cardiopulmonary resuscitation system
An integrated automated CPR system that synchronizes multiple mechanical pump modalities (circumferential thoracic and abdominal actuation) with electrical countershock to increase blood flow during cardiac arrest.
Cath lab–optimized circumferential constriction system (radiolucent variant)
Device variant and materials/design optimized for use inside catheterization/cath lab environments with radiolucent components to minimize imaging interference during interventional procedures.
Services
Collaborative design and execution of preclinical device testing in cardiac arrest animal models, including hemodynamic monitoring, injury assessment, and statistical analysis.
Integrated industrial design, mechanical/electrical engineering, software integration, and rapid prototyping for cath lab–optimized and in-hospital device variants.
Collaborative design and execution of preclinical device testing in cardiac arrest animal models, including hemodynamic monitoring, injury assessment, and statistical analysis.
Integrated industrial design, mechanical/electrical engineering, software integration, and rapid prototyping for cath lab–optimized and in-hospital device variants.
Expertise Areas
- Multimodal automated CPR system development
- Preclinical cardiac arrest models and study execution
- Pneumatic actuation systems for medical devices
- Hemodynamic monitoring and analysis
Key Technologies
- Pneumatic circumferential constriction (vest/belt) systems
- Thoracoabdominal constriction and abdominal counterpulsation
- Integrated defibrillation electrode interfaces
- Embedded control and synchronization algorithms
News & Updates
CPR Therapeutics presented seven research abstracts at the AHA-RESS, showcasing advances in multimodal CPR technology aimed at improving survival from sudden cardiac arrest.
David Gaddy, previously CTO, is now leading CPR Therapeutics as CEO, bringing over 15 years of medical device industry experience to drive innovation and growth.
The company announced it received a U.S. patent (US10,772,793 B2) for its multimodal CPR system, which combines circumferential constriction and anterior-posterior compression to improve blood flow.
The company was granted three U.S. patents in a single week, covering various innovations in CPR device technology, strengthening its intellectual property portfolio.
The NIH awarded CPR Therapeutics $1.6 million for the development of its multimodal CPR system, supporting further preclinical research and device prototyping.
The NSF awarded CPR Therapeutics a Phase I Small Business Technology Transfer (STTR) grant of $256K to support development of its innovative CPR technology.
CPR Therapeutics presented seven research abstracts at the AHA-RESS, showcasing advances in multimodal CPR technology aimed at improving survival from sudden cardiac arrest.
David Gaddy, previously CTO, is now leading CPR Therapeutics as CEO, bringing over 15 years of medical device industry experience to drive innovation and growth.
The company announced it received a U.S. patent (US10,772,793 B2) for its multimodal CPR system, which combines circumferential constriction and anterior-posterior compression to improve blood flow.
The company was granted three U.S. patents in a single week, covering various innovations in CPR device technology, strengthening its intellectual property portfolio.
The NIH awarded CPR Therapeutics $1.6 million for the development of its multimodal CPR system, supporting further preclinical research and device prototyping.
The NSF awarded CPR Therapeutics a Phase I Small Business Technology Transfer (STTR) grant of $256K to support development of its innovative CPR technology.